Biallelic Mutations in SLC1A2; an Additional Mode of Inheritance for SLC1A2-Related Epilepsy

Abstract

Recently, heterozygous de novo mutations in SCL1A2 have been reported to underlie severe early-onset epileptic encephalopathy. In one male presenting with epileptic seizures and visual impairment, we identified a novel homozygous splicing variant in SCL1A2 (c.1421 + 1G > C) by using exome sequencing. Functional studies on cDNA level confirmed a consecutive loss of function. Our findings suggest that not only de novo mutations but also biallelic variants in SLC1A2 can cause epilepsy and that there is an additional autosomal recessive mode of inheritance. These findings also contribute to the understanding of the genetic mechanism of autosomal dominant SLC1A2-related epileptic encephalopathy as they exclude haploinsufficiency as exclusive genetic mechanism.

Keywords

epilepsy - seizure - visual impairment - SLC1A2 - exome sequencing

^* These authors contributed equally to this work.

• References

• 1 Allen AS, Berkovic SF, Cossette P. , et al; Epi4K Consortium; Epilepsy Phenome/Genome Project. De novo mutations in epileptic encephalopathies. Nature 2013; 501 (7466): 217-221
• 2 Allen NM, Conroy J, Shahwan A. , et al. Unexplained early onset epileptic encephalopathy: exome screening and phenotype expansion. Epilepsia 2016; 57 (01) e12-e17
• 3 Hardies K, Weckhuysen S, De Jonghe P, Suls A. Lessons learned from gene identification studies in Mendelian epilepsy disorders. Eur J Hum Genet 2016; 24 (07) 961-967
• 4 Helbig KL, Farwell Hagman KD, Shinde DN. , et al. Diagnostic exome sequencing provides a molecular diagnosis for a significant proportion of patients with epilepsy. Genet Med 2016; 18 (09) 898-905
• 5 Mei D, Parrini E, Marini C, Guerrini R. The impact of next-generation sequencing on the diagnosis and treatment of epilepsy in paediatric patients. Mol Diagn Ther 2017; 21 (04) 357-373
• 6 Myers Candace T, McMahon Jacinta M, Schneider Amy L. , et al; Epi4K Consortium. Electronic address: [e-mail]; Epi4K Consortium. De novo mutations in SLC1A2 and CACNA1A are important causes of epileptic encephalopathies. Am J Hum Genet 2016; 99 (02) 287-298
• 7 Kim K, Lee SG, Kegelman TP. , et al. Role of excitatory amino acid transporter-2 (EAAT2) and glutamate in neurodegeneration: opportunities for developing novel therapeutics. J Cell Physiol 2011; 226 (10) 2484-2493
• 8 Kremer LS, Bader DM, Mertes C. , et al. Genetic diagnosis of Mendelian disorders via RNA sequencing. Nat Commun 2017; 8: 15824
• 9 Kopajtich R, Mayr JA, Prokisch H. Analysis of mitochondrial RNA-processing defects in patient-derived tissues by qRT-PCR and RNAseq. Methods Mol Biol 2017; 1567: 379-390
• 10 Bönnemann CG. The collagen VI-related myopathies Ullrich congenital muscular dystrophy and Bethlem myopathy. Handb Clin Neurol 2011; 101: 81-96
• 11 Gerber S, Alzayady KJ, Burglen L. , et al. Recessive and dominant de novo ITPR1 mutations cause Gillespie syndrome. Am J Hum Genet 2016; 98 (05) 971-980
• 12 Choi DW. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1988; 1 (08) 623-634
• 13 Petr GT, Sun Y, Frederick NM. , et al. Conditional deletion of the glutamate transporter GLT-1 reveals that astrocytic GLT-1 protects against fatal epilepsy while neuronal GLT-1 contributes significantly to glutamate uptake into synaptosomes. J Neurosci 2015; 35 (13) 5187-5201
• 14 Tanaka K, Watase K, Manabe T. , et al. Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. Science 1997; 276 (5319): 1699-1702
• 15 Parinejad N, Peco E, Ferreira T, Stacey SM, van Meyel DJ. Disruption of an EAAT-mediated chloride channel in a Drosophila model of ataxia. J Neurosci 2016; 36 (29) 7640-7647